SUBSCRIBE
SUBSCRIBE
News   Drug Development

Antigenics Inc. (New York) Buoyed by Brain-Cancer Study

October 26, 2009 | 
1 min read
Bookmark and Share

Drug developer Antigenics Inc. said researchers at the University of California, San Francisco, reported positive results stemming from a study using its cancer therapy Oncophage to treat brain-cancer patients.
Clinical research Phase II
MORE ON THIS TOPIC
Targeting cancer as oncology drugs and oncologist symbol for preventing malignant tumor growth disease as a symbol for pharmaceutical science and immunology or fighting human cancers.
Cancer
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
December 15, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration of businessman running back around
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hypnose eye with sharp lines. Focus illusion.
Autoimmune disease
Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials
December 15, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration showing hurdles along a path ending in an arrow
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
December 15, 2025
 · 
2 min read
 · 
Annalee Armstrong